Sporos Bioventures is a private biopharmaceutical company that aims to transform the drug development process by focusing on key mechanisms and targets of disease to accelerate drug discovery research to early clinical stage assets using a centralized infrastructure. Programs are discovered and developed by Sporos portfolio companies or by the internal Sporos biodiscovery group, which focuses on small molecules and antibody therapeutics. Sporos is headquartered in Houston with offices in New York and Boston.